The I-CreI meganuclease and its engineered derivatives: applications from cell modification to gene therapy
- PMID: 21047873
- DOI: 10.1093/protein/gzq083
The I-CreI meganuclease and its engineered derivatives: applications from cell modification to gene therapy
Abstract
Meganucleases (MNs) are highly specific enzymes that can induce homologous recombination in different types of cells, including mammalian cells. Consequently, these enzymes are used as scaffolds for the development of custom gene-targeting tools for gene therapy or cell-line development. Over the past 15 years, the high resolution X-ray structures of several MNs from the LAGLIDADG family have improved our understanding of their protein-DNA interaction and mechanism of DNA cleavage. By developing and utilizing high-throughput screening methods to test a large number of variant-target combinations, we have been able to re-engineer scores of I-CreI derivatives into custom enzymes that target a specific DNA sequence of interest. Such customized MNs, along with wild-type ones, have allowed for exploring a large range of biotechnological applications, including protein-expression cell-line development, genetically modified plants and animals and therapeutic applications such as targeted gene therapy as well as a novel class of antivirals.
Similar articles
-
Molecular basis of xeroderma pigmentosum group C DNA recognition by engineered meganucleases.Nature. 2008 Nov 6;456(7218):107-11. doi: 10.1038/nature07343. Nature. 2008. PMID: 18987743
-
Engineering of large numbers of highly specific homing endonucleases that induce recombination on novel DNA targets.J Mol Biol. 2006 Jan 20;355(3):443-58. doi: 10.1016/j.jmb.2005.10.065. Epub 2005 Nov 15. J Mol Biol. 2006. PMID: 16310802
-
A combinatorial approach to create artificial homing endonucleases cleaving chosen sequences.Nucleic Acids Res. 2006;34(22):e149. doi: 10.1093/nar/gkl720. Epub 2006 Nov 27. Nucleic Acids Res. 2006. PMID: 17130168 Free PMC article.
-
Meganucleases and DNA double-strand break-induced recombination: perspectives for gene therapy.Curr Gene Ther. 2007 Feb;7(1):49-66. doi: 10.2174/156652307779940216. Curr Gene Ther. 2007. PMID: 17305528 Review.
-
Targeted approaches for gene therapy and the emergence of engineered meganucleases.Expert Opin Biol Ther. 2009 Oct;9(10):1289-303. doi: 10.1517/14712590903213669. Expert Opin Biol Ther. 2009. PMID: 19689185 Review.
Cited by
-
5'-Cytosine-phosphoguanine (CpG) methylation impacts the activity of natural and engineered meganucleases.J Biol Chem. 2012 Aug 31;287(36):30139-50. doi: 10.1074/jbc.M112.379966. Epub 2012 Jun 27. J Biol Chem. 2012. PMID: 22740697 Free PMC article.
-
Principles of Genetic Engineering.Genes (Basel). 2020 Mar 10;11(3):291. doi: 10.3390/genes11030291. Genes (Basel). 2020. PMID: 32164255 Free PMC article. Review.
-
Improvements of nuclease and nickase gene modification techniques for the treatment of genetic diseases.Front Genome Ed. 2022 Jul 26;4:892769. doi: 10.3389/fgeed.2022.892769. eCollection 2022. Front Genome Ed. 2022. PMID: 35958050 Free PMC article. Review.
-
ITR-Seq, a next-generation sequencing assay, identifies genome-wide DNA editing sites in vivo following adeno-associated viral vector-mediated genome editing.BMC Genomics. 2020 Mar 17;21(1):239. doi: 10.1186/s12864-020-6655-4. BMC Genomics. 2020. PMID: 32183699 Free PMC article.
-
Engineered mitochondria in diseases: mechanisms, strategies, and applications.Signal Transduct Target Ther. 2025 Mar 3;10(1):71. doi: 10.1038/s41392-024-02081-y. Signal Transduct Target Ther. 2025. PMID: 40025039 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous